Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1996 Oct 1;93(20):10972–10977. doi: 10.1073/pnas.93.20.10972

Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.

L W Kwak 1, H A Young 1, R W Pennington 1, S D Weeks 1
PMCID: PMC38268  PMID: 8855293

Abstract

The idiotype of the Ig expressed by a B-cell malignancy (Id) can serve as a unique tumor-specific antigen and as a model for cancer vaccine development. In murine models of Id vaccination, formulation of syngeneic Id with carrier proteins or adjuvants induces an anti-idiotypic antibody response. However, inducing a potent cell-mediated response to this weak antigen instead would be highly desirable. In the 38C13 lymphoma model, we observed that low doses of free granulocyte/macrophage colony-stimulating factor (GM-CSF) 10,000 units i.p. or locally s.c. daily for 4 days significantly enhanced protective antitumor immunity induced by s.c. Id-keyhole limpet hemocyanin (KLH) immunization. This effect was critically dependent upon effector CD4+ and CD8+ T cells and was not associated with any increased anti-idiotypic antibody production. Lymphocytes from spleens and draining lymph nodes of mice primed with Id-KLH plus GM-CSF, but not with Id-KLH alone, demonstrated significant proliferation to Id in vitro without any biased production of interferon gamma or interleukin 4 protein or mRNA. As a further demonstration of potency, 50% of mice immunized with Id-KLH plus GM-CSF on the same day as challenge with a large s.c. tumor inoculum remained tumor-free at day 80, compared with 17% for Id-KLH alone, when immunization was combined with cyclophosphamide. Taken together, these results demonstrate that GM-CSF can significantly enhance the immunogenicity of a defined self-antigen and that this effect is mediated exclusively by activating the T-cell arm of the immune response.

Full text

PDF
10972

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnaout M. A., Wang E. A., Clark S. C., Sieff C. A. Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J Clin Invest. 1986 Aug;78(2):597–601. doi: 10.1172/JCI112615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bergman Y., Haimovich J. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol. 1977 Jul;7(7):413–417. doi: 10.1002/eji.1830070702. [DOI] [PubMed] [Google Scholar]
  3. Blanchard D. K., Djeu J. Y. Differential modulation of surface antigens on human macrophages by IFN-gamma and GM-CSF: effect on susceptibility to LAK lysis. J Leukoc Biol. 1991 Jul;50(1):28–34. doi: 10.1002/jlb.50.1.28. [DOI] [PubMed] [Google Scholar]
  4. Bogen B., Malissen B., Haas W. Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol. 1986 Nov;16(11):1373–1378. doi: 10.1002/eji.1830161110. [DOI] [PubMed] [Google Scholar]
  5. Bridges S. H. Participation of the humoral immune system in the myeloma-specific transplantation resistance. J Immunol. 1978 Aug;121(2):479–483. [PubMed] [Google Scholar]
  6. Campbell M. J., Esserman L., Byars N. E., Allison A. C., Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol. 1990 Aug 1;145(3):1029–1036. [PubMed] [Google Scholar]
  7. Campbell M. J., Esserman L., Levy R. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. J Immunol. 1988 Nov 1;141(9):3227–3233. [PubMed] [Google Scholar]
  8. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539–3543. doi: 10.1073/pnas.90.8.3539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dranoff G., Mulligan R. C. Gene transfer as cancer therapy. Adv Immunol. 1995;58:417–454. doi: 10.1016/s0065-2776(08)60624-0. [DOI] [PubMed] [Google Scholar]
  10. Eshhar Z., Blatt C., Bergman Y., Heimovich J. Induction of secretion of IgM from cells of the B cell line 38c-13 by somatic cell hybridization. J Immunol. 1979 Jun;122(6):2430–2434. [PubMed] [Google Scholar]
  11. Fischer H. G., Frosch S., Reske K., Reske-Kunz A. B. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J Immunol. 1988 Dec 1;141(11):3882–3888. [PubMed] [Google Scholar]
  12. Freedman P. M., Autry J. R., Tokuda S., Williams R. C., Jr Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein. J Natl Cancer Inst. 1976 Apr;56(4):735–740. doi: 10.1093/jnci/56.4.735. [DOI] [PubMed] [Google Scholar]
  13. George A. J., Tutt A. L., Stevenson F. K. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J Immunol. 1987 Jan 15;138(2):628–634. [PubMed] [Google Scholar]
  14. Golumbek P. T., Azhari R., Jaffee E. M., Levitsky H. I., Lazenby A., Leong K., Pardoll D. M. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res. 1993 Dec 15;53(24):5841–5844. [PubMed] [Google Scholar]
  15. Grabstein K. H., Urdal D. L., Tushinski R. J., Mochizuki D. Y., Price V. L., Cantrell M. A., Gillis S., Conlon P. J. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science. 1986 Apr 25;232(4749):506–508. doi: 10.1126/science.3083507. [DOI] [PubMed] [Google Scholar]
  16. Heufler C., Koch F., Schuler G. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med. 1988 Feb 1;167(2):700–705. doi: 10.1084/jem.167.2.700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Huang A. Y., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 1994 May 13;264(5161):961–965. doi: 10.1126/science.7513904. [DOI] [PubMed] [Google Scholar]
  18. Jørgensen T., Gaudernack G., Hannestad K. Immunization with the light chain and the VL domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC315. Scand J Immunol. 1980;11(1):29–35. doi: 10.1111/j.1365-3083.1980.tb00205.x. [DOI] [PubMed] [Google Scholar]
  19. Kaminski M. S., Kitamura K., Maloney D. G., Levy R. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol. 1987 Feb 15;138(4):1289–1296. [PubMed] [Google Scholar]
  20. Kwak L. W., Campbell M. J., Czerwinski D. K., Hart S., Miller R. A., Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992 Oct 22;327(17):1209–1215. doi: 10.1056/NEJM199210223271705. [DOI] [PubMed] [Google Scholar]
  21. Kwak L. W., Campbell M. J., Zelenetz A. D., Levy R. Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy. Blood. 1991 Nov 15;78(10):2768–2772. [PubMed] [Google Scholar]
  22. Kwak L. W., Taub D. D., Duffey P. L., Bensinger W. I., Bryant E. M., Reynolds C. W., Longo D. L. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet. 1995 Apr 22;345(8956):1016–1020. doi: 10.1016/s0140-6736(95)90757-2. [DOI] [PubMed] [Google Scholar]
  23. Lauritzsen G. F., Weiss S., Dembic Z., Bogen B. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5700–5704. doi: 10.1073/pnas.91.12.5700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Lynch R. G., Graff R. J., Sirisinha S., Simms E. S., Eisen H. N. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci U S A. 1972 Jun;69(6):1540–1544. doi: 10.1073/pnas.69.6.1540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Morrissey P. J., Bressler L., Park L. S., Alpert A., Gillis S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol. 1987 Aug 15;139(4):1113–1119. [PubMed] [Google Scholar]
  26. Sakato N., Eisen H. N. Antibodies to idiotypes of isologous immunoglobulins. J Exp Med. 1975 Jun 1;141(6):1411–1426. doi: 10.1084/jem.141.6.1411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Santoli D., Clark S. C., Kreider B. L., Maslin P. A., Rovera G. Amplification of IL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor. J Immunol. 1988 Jul 15;141(2):519–526. [PubMed] [Google Scholar]
  28. Sirisinha S., Eisen H. N. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Natl Acad Sci U S A. 1971 Dec;68(12):3130–3135. doi: 10.1073/pnas.68.12.3130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Smith P. D., Lamerson C. L., Wong H. L., Wahl L. M., Wahl S. M. Granulocyte-macrophage colony-stimulating factor stimulates human monocyte accessory cell function. J Immunol. 1990 May 15;144(10):3829–3834. [PubMed] [Google Scholar]
  30. Steis R. G., VanderMolen L. A., Longo D. L., Clark J. W., Smith J. W., 2nd, Kopp W. C., Ruscetti F. W., Creekmore S. P., Elwood L. J., Hursey J. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial. J Natl Cancer Inst. 1990 Apr 18;82(8):697–703. doi: 10.1093/jnci/82.8.697. [DOI] [PubMed] [Google Scholar]
  31. Stevenson F. K., Gordon J. Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation. J Immunol. 1983 Feb;130(2):970–973. [PubMed] [Google Scholar]
  32. Stevenson F. K., Zhu D., King C. A., Ashworth L. J., Kumar S., Hawkins R. E. Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev. 1995 Jun;145:211–228. doi: 10.1111/j.1600-065x.1995.tb00083.x. [DOI] [PubMed] [Google Scholar]
  33. Sugai S., Palmer D. W., Talal N., Witz I. P. Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice. J Exp Med. 1974 Dec 1;140(6):1547–1558. doi: 10.1084/jem.140.6.1547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Tao M. H., Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature. 1993 Apr 22;362(6422):755–758. doi: 10.1038/362755a0. [DOI] [PubMed] [Google Scholar]
  35. Young D. A., Lowe L. D., Clark S. C. Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. Analysis of macrophage antibody-dependent cellular cytotoxicity. J Immunol. 1990 Jul 15;145(2):607–615. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES